Search results for "346"

showing 10 items of 252 documents

Early Referral to an ALS Center Reduces Several Months the Diagnostic Delay: A Multicenter-Based Study.

2020

Objective: To analyze those factors contributing to the diagnostic delay in ALS.Methods: Consecutive ALS patients were categorized as those studied in departmental hospitals and those studied in a referral ALS center. Demographic and clinical variables, together with data of the diagnostic pathway were collected. Multivariable models were used to assess their effect in the time between symptoms onset and the first neurologist visit (time symptoms-neurologist), in the time between the first neurologist visit and the diagnosis (time neurologist-diagnosis) and in the diagnostic delay.Results: 166 ALS patients with a median diagnostic delay of 11.53 months (IQR: 6.68, 15.23) were included. The …

Pediatricsmedicine.medical_specialtyamyotrophic lateral sclerosisALS UnitClinical variablesReferrallcsh:RC346-42903 medical and health sciences0302 clinical medicinemental disordersmedicine030212 general & internal medicineAmyotrophic lateral sclerosislcsh:Neurology. Diseases of the nervous systemOriginal Researchdiagnostic timelinesbusiness.industryUpper motor neuronmedicine.diseasediagnostic delaynervous system diseasesdiagnostic pathwaymedicine.anatomical_structureNeurologyReferral centerBulbar onsetProgression rateNeurology (clinical)business030217 neurology & neurosurgeryEarly referralFrontiers in neurology
researchProduct

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

2021

Background and aims: No consensus exists on how aggressively to treat relapsing–remitting multiple sclerosis (RRMS) nor on the timing of the treatment. The objective of this study was to evaluate disability trajectories in RRMS patients treated with an early intensive treatment (EIT) or with a moderate-efficacy treatment followed by escalation to higher-efficacy disease modifying therapy (ESC). Methods: RRMS patients with ⩾5-year follow-up and ⩾3 visits after disease modifying therapy (DMT) start were selected from the Italian MS Registry. EIT group included patients who received as first DMT fingolimod, natalizumab, mitoxantrone, alemtuzumab, ocrelizumab, cladribine. ESC group patients rec…

Pediatricsmedicine.medical_specialtybig data; disability trajectories; disease registry; multiple sclerosis.multiple sclerosis03 medical and health sciences0302 clinical medicineDisease registrybig dataMedicine030212 general & internal medicineRC346-429Original Researchbig data; disability trajectories; disease registry; multiple sclerosisPharmacologybusiness.industryMultiple sclerosisLong term disabilitymedicine.diseaseNeurologydisease registryTreatment strategySettore MED/26 - Neurologiadisability trajectoriesNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.

2017

Background: Up to every fourth woman with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) suffers a clinically relevant relapse during pregnancy. High doses of steroids bear some serious risks, especially within the first trimester of pregnancy. Immunoadsorption (IA) is an effective and more selective treatment option in disabling MS relapse than plasma exchange. Data on the use of IA during pregnancy and breastfeeding are scarce. Methods: In this retrospective multicenter study, we analyzed the safety and efficacy of IA treatment in acute relapses during pregnancy or breastfeeding. The primary outcome parameter - change of acute relapse-related disability after IA…

Pediatricsmedicine.medical_specialtybreastfeedingBreastfeeding030204 cardiovascular system & hematologymultiple sclerosislcsh:RC346-42903 medical and health sciences0302 clinical medicineplasma exchangeHigh dosesMedicineIn patientSpectrum disorderImmunoadsorptionlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyrelapsePregnancytherapyNeuromyelitis opticabusiness.industryMultiple sclerosisneuromyelitis optica spectrum disordermedicine.diseaseeye diseasesNeurologyNeurology (clinical)pregnancybusiness030217 neurology & neurosurgeryimmunoadsorptionTherapeutic advances in neurological disorders
researchProduct

Intra- and Interrater Reliability of Sagittal Spinopelvic Parameters on Full-Spine Radiographs in Adults With Symptomatic Spinal Disorders

2018

Background/Aims To evaluate the intra- and interrater reliability (I-IR) of sagittal spinopelvic parameters from digital full-spine plain radiographs with basic software tools in an unselected adult population with degenerative spinal complaints who were evaluated for surgery. Methods Forty-nine adult full-spine digital radiographs were measured twice by 3 independent observers, including an experienced spine surgeon, an experienced radiologist, and a resident orthopedic surgeon. Clinical picture archiving and communication system workstations and software tools were used and landmarks were set manually. The I-IR of the sagittal vertical axis (SVA), pelvic tilt (PT), pelvic incidence (PI), …

Pelvic tiltmedicine.medical_specialtyIntraclass correlationradiographic imagediagnostic imagingRadiographyScoliosis/diagnostic imagingskolioosiSurgical planninglcsh:RC346-42903 medical and health sciences0302 clinical medicineselkäsairaudetmedicinestandarditta315lcsh:Neurology. Diseases of the nervous systemOrthodontics030222 orthopedicsscoliosisbusiness.industrysoftwareadultröntgentutkimusta3141RepeatabilitySagittal planeobserver variationInter-rater reliabilitymedicine.anatomical_structurekuvantaminenOrthopedic surgerystandardsSoftware/standardsOriginal ArticleSurgeryNeurology (clinical)reproducibility of resultsbusinessdiagnoosi030217 neurology & neurosurgeryNeurospine
researchProduct

Temperamental characteristics in childhood migraine without aura: a multicenter study

2013

Maria Esposito,1 Rosa Marotta,2 Beatrice Gallai,3 Lucia Parisi,4 Giuseppina Patriciello,1 Serena Marianna Lavano,2 Giovanni Mazzotta,5 Michele Roccella,4 Marco Carotenuto11Center for Childhood Headache, Clinic of Child and Adolescent Neuropsychiatry, Department of Mental Health, Physical and Preventive Medicine, Second University of Naples, Naples, Italy; 2Department of Psychiatry, "Magna Graecia" University of Catanzaro, Catanzaro, Italy; 3Unit of Child and Adolescent Neuropsychiatry, University of Perugia, Perugia, Italy; 4Child Neuropsychiatry, Department of Psychology, University of Palermo, Palermo, Italy; 5Unit of Child and Adolescent Neuropsychiatry, AUSL Umbria 2, …

Persistence (psychology)medicine.medical_specialtyNeuropsychiatric Disease and TreatmentAuramedia_common.quotation_subjectNeurosciences. Biological psychiatry. NeuropsychiatrychildrenMedicinejTCIPsychiatryRC346-429Biological Psychiatrymedia_commonOriginal ResearchChildhood migrainebusiness.industrytemperamentmedicine.diseasePsychiatry and Mental healthMulticenter studyMigrainemigraine without auraHarm avoidanceTemperament and Character InventoryTemperamentNeurology. Diseases of the nervous systembusinessClinical psychologyRC321-571
researchProduct

Age and Cytokine Gene Variants Modulate the Immunogenicity and Protective Effect of SARS-CoV-2 mRNA-Based Vaccination

2023

The introduction of anti-SARS-CoV-2 vaccines in late 2020 substantially changed the pandemic picture, inducing effective protection in the population. However, individual variability was observed with different levels of cellular response and neutralizing antibodies. We report data on the impact of age, gender, and 16 single nucleotide polymorphisms (SNPs) of cytokine genes on the anti-SARS-CoV-2 IgG titers measured 31 and 105 days after administration of the second dose of BNT162b2 vaccine to 122 healthy subjects from the health care staff of the Palermo University Hospital, Italy. The higher titers at 31 days were measured in the younger subjects and in subjects bearing T-positive genotyp…

PharmacologyTNFA rs1800629anti-SARS-CoV-2 S1/S2 IgGanti-SARS-CoV-2 vaccineSettore MED/07 - Microbiologia E Microbiologia ClinicaImmunologyanti-SARS-CoV-2 vaccine; anti-SARS-CoV-2 S1/S2 IgG; cytokine gene SNPs; <i>IL-1R1 rs2234650</i>; <i>IL-6 rs1800795</i>; <i>IL-4 rs2243250</i>; <i>TNFA rs1800629</i>IL-1R1 rs2234650Infectious DiseasesIL-4 rs2243250Drug DiscoveryIL-6 rs1800795Settore MED/05 - Patologia ClinicaPharmacology (medical)cytokine gene SNPs.
researchProduct

Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis

2021

Background: Serum neurofilament light chain (sNfL) is a promising biomarker to complement the decision-making process in multiple sclerosis (MS) patients. However, although sNfL levels are able to detect disease activity and to predict future disability, the growing evidence has not yet been translated into practicable recommendations for an implementation into clinical routine. Methods: The observation of a patient with extensive inflammatory activity in magnetic resonance imaging (MRI) along with an extremely high sNfL level in the absence of any clinical symptoms prompted us to investigate common characteristics of our MS patients with the highest sNfL levels in a retrospective cohort st…

Pharmacologybusiness.industrysubclinical disease activityNeurofilament lightMultiple sclerosismultiple sclerosismedicine.diseaseextreme levels03 medical and health sciencesneurofilament light chain0302 clinical medicineNeurologyImmunologymedicinebiomarkerBiomarker (medicine)Neurology. Diseases of the nervous system030212 general & internal medicineNeurology (clinical)RC346-429business030217 neurology & neurosurgeryOriginal ResearchTherapeutic Advances in Neurological Disorders
researchProduct

A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice

2021

Translational animal models for studying post-traumatic stress disorder (PTSD) are valuable for elucidating the poorly understood neurobiology of this neuropsychiatric disorder. These models should encompass crucial features, including persistence of PTSD-like phenotypes triggered after exposure to a single traumatic event, trauma susceptibility/resilience and predictive validity. Here we propose a novel arousal-based individual screening (AIS) model that recapitulates all these features. The AIS model was designed by coupling the traumatization (24 h restraint) of C57BL/6 J mice with a novel individual screening. This screening consists of z-normalization of post-trauma changes in startle …

Physiology5-trial SM 5-trial social memoryBiochemistryFight-or-flight responseFST forced swim test0302 clinical medicineEndocrinologySSRIs selective serotonin reuptake inhibitorsDSM-5 Diagnostic and Statistical Manual of Mental DisordersOriginal Research ArticleFear conditioningmedia_commonHT hypothalamusAIS arousal-based individual screeningQP351-495ParoxetinePhenotypeHPA hypothalamic–pituitary–adrenalBST basal synaptic transmissionHIP hippocampusPTSD post-traumatic stress disorder[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Psychological resilienceAmy amygdalaRC321-571medicine.drugNeurophysiology and neuropsychologymedia_common.quotation_subjectBDNF brain derived neurotropic factorFear conditioningNeurosciences. Biological psychiatry. NeuropsychiatryBiologyStressArousal03 medical and health sciencesCellular and Molecular NeuroscienceAnimal model Fear conditioning Resilience Stress Susceptibility Z-scoreAnimal modelCORT corticosteroneOF open fieldTE trauma-exposedBiological neural networkmedicineAnimal model[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]C controlfEPSPs field excitatory post-synaptic potentialsSGK1 serum/glucocorticoid-regulated kinase 1RC346-429Molecular BiologyResilienceEndocrine and Autonomic SystemsZ-scoremPFC medial prefrontal cortexFKBP5 FK506 binding protein 5FDA Food and Drug AdministrationASR acoustic startle reactivityEPM elevated plus maze030227 psychiatrySusceptibilityAnimal model; Fear conditioning; Resilience; Stress; Susceptibility; Z-scoreNeurology. Diseases of the nervous systemNeuroscience030217 neurology & neurosurgeryNeurobiology of Stress
researchProduct

A review of the neurobiological basis of dyslexia in the adult population

2017

Introduction: Adult dyslexia affects about 4% of the population. However, studies on the neurobiological basis of dyslexia in adulthood are scarce compared to paediatric studies. Aim: This review investigates the neurobiological basis of dyslexia in adulthood. Development: Using PsycINFO, a database of psychology abstracts, we identified 11 studies on genetics, 9 neurostructural studies, 13 neurofunctional studies and 24 neurophysiological studies. Results from the review show that dyslexia is highly heritable and displays polygenic transmission. Likewise, adult neuroimaging studies found structural, functional, and physiological changes in the parieto-occipital and occipito-temporal region…

PopulationAdult populationInferior frontal gyrusPsycINFObehavioral disciplines and activitiesBiological theories of dyslexialcsh:RC346-429050105 experimental psychologyDevelopmental psychology03 medical and health sciences0302 clinical medicineNeuroimagingmental disordersmedicine0501 psychology and cognitive scienceseducationlcsh:Neurology. Diseases of the nervous systemeducation.field_of_study05 social sciencesDyslexiamedicine.diseaseSpellingnervous system diseasesPsychologypsychological phenomena and processes030217 neurology & neurosurgeryNeurología (English Edition)
researchProduct

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

2021

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particular…

Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine &amp; healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct